News coverage about Avinger (NASDAQ:AVGR) has been trending somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Avinger earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned headlines about the medical device company an impact score of 47.1024583602656 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
Separately, Ladenburg Thalmann initiated coverage on Avinger in a research note on Friday, March 9th. They issued a “buy” rating for the company.
Avinger traded up $0.01, reaching $1.25, during mid-day trading on Tuesday, MarketBeat Ratings reports. The stock had a trading volume of 373,700 shares, compared to its average volume of 850,555. The company has a market capitalization of $6.00 million, a price-to-earnings ratio of -0.02 and a beta of 0.55. Avinger has a 1-year low of $1.18 and a 1-year high of $1.22.
Avinger (NASDAQ:AVGR) last posted its quarterly earnings results on Monday, May 14th. The medical device company reported ($5.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.84) by ($4.53). The company had revenue of $1.81 million during the quarter. analysts expect that Avinger will post -1.93 earnings per share for the current fiscal year.
In other news, insider Himanshu Patel purchased 50 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was acquired at an average cost of $1,000.00 per share, for a total transaction of $50,000.00. Following the completion of the purchase, the insider now owns 2,484 shares of the company’s stock, valued at $2,484,000. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.80% of the stock is currently owned by company insiders.
Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.
Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.